



**Doncaster Place & Bassetlaw Place Medicines Optimisation
Committee (PMOC)
Sections 1&2 (Area Prescribing and Formulary)
Thursday 19th February 2026 12:00 noon
Via MS Teams
Minutes**

Committee Members:	✓ x	Area Prescribing	Formulary
Rao Kolusu (Chair) Doncaster Place	RK	✓	✓
Ewa Gabzdyl (Deputy Chair) (1 rep from Doncaster Place)	EG	✓	✓
Erica Carmody (only when EG cannot attend)	EC	x	x
Rob Wise Bassetlaw Place	RW	✓	✓
Lee Wilson DBTHFT (1 rep from DBTHFT)	LW	✓	✓
Rachel Wilson DBTHFT (when LW cannot attend)	RaW	x	x
Steve Davies RDaSH FT (1 rep from RDaSH FT)	SD	x	x
Andrew Houston RDaSH FT	AHo	x	x
Rachel Hubbard Doncaster Place	RH	x	x
Mallicka Chakrabarty Bassetlaw (Area Prescribing only)	MC	✓	✓
Dean Eggitt LMC	DE	✓	✓
Rumit Shah LMC (when DE cannot attend)	RS	x	x
Sonia Griffiths (Mount Group Practice)	SG	✓	✓
Pankaj Chatuvedi DBTHFT (Formulary only)	PC	x	x
Charlotte McMurray (SY ICB MO Team) (Only when needed)	CMcM	x	x
Ashley Hill Doncaster MOT (only when needed)	AH	x	x
Karen Jennison Doncaster MOT	KJ	✓	✓
Eve Bucktrout Doncaster MOT	EB	✓	✓
In attendance:			
Sarah Hutchinson			
Tracey White			
Layla Smith			
Amina Hussain (12:00-12:40)			

✓ x – Indication of attendance to each section of the meeting (where required to attend)

SY ICB – South Yorkshire Integrated Care Board

SY – South Yorkshire

IMOC – Integrated Medicines Optimisation Committee

PMOC – Place Medicines Optimisation Committee

MOT – Medicines Optimisation Team

MO – Medicines Optimisation

TLS – Traffic Light System

MPD- Medicines and Product Directory

SCP – Shared Care Protocol

GP- General Practitioner



Agenda Ref	Subject / Action Required	Action Required By
	Welcome, Introductions and Housekeeping: - Fire Alarm Procedure: N/A	
	Apologies for Absence: Apologies were received from Rachel Hubbard In attendance: Sarah Hutchinson Tracey White Layla Smith Amina Hussain The meeting was noted at Quorate.	
	Declarations of Interest ICB Register of Interests Ewa Gabzdyl declared that she attended the advisory board for Kelso Pharma regarding Midazolam nasal spray. Eve Bucktrout declared that she is possibly participating in a clinical trial for Rimegepant and may receive payment.	
	Notification of Any Other Business <ul style="list-style-type: none"> • Ewa Gabzdyl – Rybelsus update • Rao Kolusu – Future of the PMOC meeting • Lee Wilson – DBTHFT plan to switch formulary choice from Dalteparin to Enoxaparin 	
02/26/1	Minutes and actions of the last Meeting The minutes of the meeting held in January 2026 were approved as a true record with the following amendments: - <ul style="list-style-type: none"> ➤ 01/26/7.1 - Ewa Gabzdyl highlighted that biosimilar drugs are generic drugs which can be substituted for biologics (biologics replaced high-cost drugs). ➤ Sonia Griffiths requested a change of employer from PCD 4D to Mount Group Practice. Action: <ul style="list-style-type: none"> • Eve Bucktrout will distribute the ratified minutes to the appropriate distribution list. Action log The action log was discussed and updated accordingly.	EB
02/26/2	Matters arising not on the agenda	
12/25/4.1	Rheumatology SCP	



	<p>The final draft documents version 8.2 was presented to the group for final approval; this contains the changes requested by Chee-Seng Yee Rheumatology Consultant at DBTHFT. The group acknowledged the changes highlighted and approved the documents. These will now be finalised and uploaded onto the MO website with a link to the MPD and be included in the next bulletin.</p> <p>Action:</p> <ul style="list-style-type: none"> • Karen Jennison will replace the old version with version 8.2 on the MO website and link to the MPD. It will also be included in the next MO bulletin. 	KJ
02/26/3	Matters Arising	
09/25/1.4.3	<p>Hydroxychloroquine retinal screening update</p> <p>The group received an email from Karl Roberts, who informed the group that the contract has been renewed until the 31st of March 2028. Discussions around the concerns raised with the providers and commissioners of the service will continue. Karl Roberts advised the group that a representative from PMOC could arrange a meeting with the provider and commissioner to further discuss the issues raised and ensure that the relevant assurances/actions are put in place.</p> <p>The group noted that the contract was to continue and moving forward the priority will be to check that the process is being carried out properly. It was agreed that this was more of a commissioning responsibility than a clinical issue. In light of the organisational change, it is unclear who will be responsible for this, but it is hoped that commissioning colleagues who transition into the new organisation will pick this work up. The group believe that good communication between SpaMedica and DBTHFT is crucial to ensure success of this service.</p> <p>There are no actions required by PMOC, any further updates can be brought back to future meetings.</p>	
11/25/1.4.2	<p>Shared Care process (Lithium) – requests from Primary care to secondary care where there is no shared care agreement in place. E.g. new patients who are already on an Amber drug. Unfortunately, there was no representative from RDaSHFT so there was no discussion, but it was agreed that Ewa Gabzdył would contact Manjeet Kaur Deputy Chief Pharmacist and Medicine Safety Officer to ask for assurance of the process and to ask if a representative would be attending future PMOC meetings.</p> <p>Action:</p> <ul style="list-style-type: none"> • Ewa Gabzdył to contact Manjeet Kaur Deputy Chief Pharmacist and Medicine Safety Officer to ask for assurance of the process and to ask if a representative would be attending future PMOC meetings. 	EG
02/26/4	New Business	



02/26/4.1	<p>SY Respiratory Formulary</p> <p>Ewa Gabzdyl presented the SY Respiratory Formulary which contained the asthma guidance for adults and the COPD guidance. The group reviewed the documents and discussed the products proposed as additions to the formulary. There was a discussion around the number of products on the documents, containing a larger selection than in Doncaster's previous guidance. It was acknowledged that this may be helpful for some clinicians, it may also cause confusion when prescribing. It was also acknowledged that the SY wide guidance is more inclusive and ensures that all patients have access to the same medication across South Yorkshire.</p> <p>Action:</p> <ul style="list-style-type: none"> • Karen Jennison to add Trixeo as first line triple therapy for COPD and change Trimbaw to third line triple therapy for COPD. • Karen Jennison to also add Spiolto Respimat as 2nd line for COPD. 	KJ
-----------	---	----

02/26/5	<p>Formulary and MPD (Medicines and Products Directory) review February 2026. The formulary products were agreed as below:</p> <table border="1" data-bbox="261 909 1366 1727"> <thead> <tr> <th>Formulary Section</th> <th>Item</th> <th>Indication</th> <th>PMOC Action</th> </tr> </thead> <tbody> <tr> <td>4.7.4</td> <td>Atogepant</td> <td>Prevention of episodic and chronic migraine</td> <td>Added to MPD as Amber G</td> </tr> <tr> <td>4.7.4</td> <td>Rimegepant</td> <td>Prevention of episodic migraine</td> <td>Added to MPD as Amber G</td> </tr> <tr> <td>3.2</td> <td>Trixeo (ICS/LABA/LAMA triple therapy)</td> <td>COPD</td> <td>Amended from 2nd line to 1st line</td> </tr> <tr> <td>3.2</td> <td>Trimbaw (ICS/LABA/LAMA triple therapy)</td> <td>COPD</td> <td>Amended from 1st line to 3rd line</td> </tr> <tr> <td>3.1.4</td> <td>Spiolto Respimat</td> <td>COPD</td> <td>Added to MPD as 2nd line</td> </tr> <tr> <td>4.5.2</td> <td>Tirzepatide</td> <td>Weight management</td> <td>New status – Grey (any patients that fall out of NICE guidance TA1026)</td> </tr> <tr> <td>7.1.1</td> <td>Progesterone 400mg soft vaginal capsules</td> <td>Indicated for the prevention of miscarriage in women presenting with bleeding in the first trimester of pregnancy and have a history of recurrent miscarriages.</td> <td>Added to MPD as Amber G</td> </tr> <tr> <td>4.9.3</td> <td>Primidone</td> <td>Essential Tremor</td> <td>Added to MPD as green</td> </tr> <tr> <td>17.2</td> <td>Intravaginal device, ring and shelf pessaries</td> <td>Non-surgical management of pelvic floor dysfunction</td> <td>Added to MPD as green</td> </tr> </tbody> </table> <p>The antibiotic section was reviewed by Lee Wilson, and some TLS statuses were amended from red to hospital only as this status reflects products that are formulary in secondary care. The group approved all changes on the MPD. Section 5.1.8 will be reviewed in the future.</p> <p>Glaucoma cost effective switches will be added to the MPD to advise prescribers of the cost-effective brands. Ewa Gabzdyl will contact Dr Kayarkar</p>	Formulary Section	Item	Indication	PMOC Action	4.7.4	Atogepant	Prevention of episodic and chronic migraine	Added to MPD as Amber G	4.7.4	Rimegepant	Prevention of episodic migraine	Added to MPD as Amber G	3.2	Trixeo (ICS/LABA/LAMA triple therapy)	COPD	Amended from 2 nd line to 1 st line	3.2	Trimbaw (ICS/LABA/LAMA triple therapy)	COPD	Amended from 1 st line to 3 rd line	3.1.4	Spiolto Respimat	COPD	Added to MPD as 2 nd line	4.5.2	Tirzepatide	Weight management	New status – Grey (any patients that fall out of NICE guidance TA1026)	7.1.1	Progesterone 400mg soft vaginal capsules	Indicated for the prevention of miscarriage in women presenting with bleeding in the first trimester of pregnancy and have a history of recurrent miscarriages.	Added to MPD as Amber G	4.9.3	Primidone	Essential Tremor	Added to MPD as green	17.2	Intravaginal device, ring and shelf pessaries	Non-surgical management of pelvic floor dysfunction	Added to MPD as green	
Formulary Section	Item	Indication	PMOC Action																																							
4.7.4	Atogepant	Prevention of episodic and chronic migraine	Added to MPD as Amber G																																							
4.7.4	Rimegepant	Prevention of episodic migraine	Added to MPD as Amber G																																							
3.2	Trixeo (ICS/LABA/LAMA triple therapy)	COPD	Amended from 2 nd line to 1 st line																																							
3.2	Trimbaw (ICS/LABA/LAMA triple therapy)	COPD	Amended from 1 st line to 3 rd line																																							
3.1.4	Spiolto Respimat	COPD	Added to MPD as 2 nd line																																							
4.5.2	Tirzepatide	Weight management	New status – Grey (any patients that fall out of NICE guidance TA1026)																																							
7.1.1	Progesterone 400mg soft vaginal capsules	Indicated for the prevention of miscarriage in women presenting with bleeding in the first trimester of pregnancy and have a history of recurrent miscarriages.	Added to MPD as Amber G																																							
4.9.3	Primidone	Essential Tremor	Added to MPD as green																																							
17.2	Intravaginal device, ring and shelf pessaries	Non-surgical management of pelvic floor dysfunction	Added to MPD as green																																							



	<p>to obtain the secondary care perspective on the proposed cost-effective preparations.</p> <p>Action:</p> <ul style="list-style-type: none"> • Karen Jennison will make the agreed amendments to the MPD. • Ewa Gabzdyl to contact Dr Kayarkar to obtain the secondary care perspective on the proposed cost-effective preparations. 	KJ EG
02/26/6	Any Other Business	
02/26/6.1	<p>Rybelsus</p> <p>Ewa Gabzdyl updated the group on the progress of the switch from the first generation to second generation Rybelsus. The leadership team are running regular searches to ascertain the number of patients remaining on the first generation, currently there are less than 150 patients left on the first generation. The production of the first generation Rybelsus has stopped. Lee Wilson has shared information with the pharmacy team and prescribers at DBTHFT regarding safety and switching. Steps have been taken to ensure safe transition and any remaining first-generation stock will be destroyed. It was highlighted by Ewa Gabzdyl that an MHRA alert has been released regarding the worsening of eyesight whilst on this medication.</p>	
02/26/6.2	<p>DBTHFT plan to switch formulary choice from Dalteparin to Enoxaparin</p> <p>Lee Wilson informed the group of the intension to change the choice of low molecular weight heparin from Dalteparin to Enoxaparin. The policy and shared cared protocol will be updated to reflect this change and will be taken to IMOC for approval. All four places in South Yorkshire are planning to use Enoxaparin as first line choice.</p>	
02/26/6.3	<p>Future of the PMOC meeting</p> <p>Rao Kolusu informed the group that he attended a meeting regarding the future of PMOC and equivalent meetings in Barnsley, Rotherham and Sheffield. There was a strong feeling amongst the attendees to continue meetings at place level. It was noted that during the transition and beyond, staff levels will be considerably lower at the ICB. There was an acknowledgment that place based work is valuable and will be missed if stopped. Rao Kolusu said that it was suggested at the meeting that providers could carry this on in the future however this is yet to be confirmed. Rao Kolusu acknowledged the good work that PMOC does cascading information to general practice.</p> <p>It was suggested to discuss further the possibility of the providers continuing to meet at place level. It was noted that Doncaster and Bassetlaw have links that need to be maintained in order for patients to continue to receive standardised services.</p> <p>Further discussions will be held at future meetings.</p>	
02/26/7	Standing Prescribing functions	
02/26/7.1	<p>The committee received the TLS list that was agreed at the February 2026 IMOC meetings.</p> <p>Please Note:</p>	



TLS status finalised at IMOC all items are classified as non-Formulary unless stated otherwise.

The following have been agreed as **Grey**:

Drug/Product	rationale
Tepilizumab	6
Entrectinib	7

The following have been agreed as **Red**:

Obecabtagene autoleucl	1,6
Buprenorphine/naloxone	1
Buprenorphine	1
Calcium Polystyrene Sulfonate	1
Clobazam	1
Dostarlimab with platinum-containing chemotherapy	1,6
Venetoclax with obinutuzumab	1,6
Avelumab with axitinib	1,6
Acoramidis	1,6
Amivantamab with lazertinib	1,6
Relugolix 120mg tablets	1,7

The following has been agreed as **Amber-G**:

latanoprost/netarsudil eye drops
Atogepant
Rimegepant
Progesterone 400mg soft vaginal capsules - Prometrium® (formulation)

The following has been agreed as **Green**:

Primidone for essential Tremor
Intravaginal device and pessaries- non-surgical management of pelvic floor dysfunction
Buprenorphine - Pain
Varenicline-Smoking cessation - Already classified green on the SY TLDL at chemical substance level with the wording: Please refer to Place Commissioned services and guidance documents. In exceptional circumstances, for patients who are unable to access these services, primary care can prescribe. Please see CKS for supporting information.

Action:

- Karen Jennison to update the MPD

KJ

02/26/7.2

NICE Guidance

The NICE guidance report was received that was discussed at the February 2026 IMOC meeting.

Ewa Gabzdyl informed the group of the NICE guidance discussed at the February IMOC

There were no actions for this group.

02/26/7.3

MHRA - Drug Safety Update & NHS England Patient Safety alerts

The Safety report that was discussed at the February 2026 IMOC meeting was received.

Ewa Gabzdyl informed the group of the items included in the safety report highlighting: -

- Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs

Action:

- Karen Jennison to add this safety update to the next MO bulletin.

KJ



02/26/7.4	<p>IMOC Update – February 2026 IMOC meeting new documents that have been added to SY MO website/ link to MPD: -</p> <ul style="list-style-type: none"> • Tirzepatide weight management patient information leaflet (short version) approved and live on the MO website (link on MPD) • Daridorexant traffic light status green approved, awaiting final document • SY Asthma and COPD guidance were approved • Migraine documents update - amber G documents for Atogepant and Rimegepant (prevention) are now live on the MO website (link on MPD) • 3rd party ordering position statement - was approved and will be uploaded on the MO website in due course <p>Action</p> <ul style="list-style-type: none"> • Karen Jennison to include in the next MO bulletin for information 	KJ
01/26/8	<p>Minutes from other groups</p>	
	<p>SY ICB IMOC Minutes from January 2026 were received for information.</p>	
	<p>DBTHFT Drug & Therapeutics Committee (Monthly) Minutes from December 2025 and January 2026 were received for information.</p>	
	<p>RDASH FT TMOG (Monthly) No minutes available for this meeting.</p>	
	<p>Barnsley Place APC No minutes available for this meeting.</p>	
	<p>Rotherham Place MMC Minutes from January 2026 were received for information.</p>	
	<p>Sheffield Place APG Minutes from January 2026 were received for information.</p>	
	<p>Nottinghamshire No minutes available for this meeting</p>	
	<p>Date and Time of Next Meeting The next PMOC meeting will be held on Thursday 19th March 2026 at 12:00 Noon Via Teams Karen Jennison and Mallicka Chakrabarty have given apologies for the March meeting.</p>	

